Breaking News

Janssen, ViiV to Develop Single Tablet Regimen for HIV

June 12, 2014

Aims to offer a better treatment option for patients

Janssen R&D Ireland has entered a collaboration with ViiV Healthcare to develop and commercialize a new single tablet regimen containing Janssen's Non-Nucleoside Reverse Transcriptase Inhibitor rilpivirine (EDURANT) and ViiV's Integrase Inhibitor dolutegravir (TIVICAY), as the sole active ingredients for the maintenance treatment of HIV. The companies will also investigate development of the drug combination for pediatric use.
 
If approved, this treatment could offer an option for patients to switch from a standard three-drug therapy to a two-drug, Nucleoside Reverse Transcriptase Inhibitor (NRTI)-sparing antiviral regimen.  
 
"HIV remains a significant medical challenge, and our goal is to find new treatment regimens for patients," said Paul Stoffels, chief scientific officer, Johnson & Johnson and Worldwide Chairman, Janssen. "We are pleased to collaborate with ViiV Healthcare in pursuing this shift in the HIV treatment paradigm and reaffirm our commitment to collaborate and develop new HIV treatments and fixed-dose regimens."

Related Contract Manufacturing:

blog comments powered by Disqus
  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • The Role of Alliances in Modern Drug Development

    The Role of Alliances in Modern Drug Development

    Dr. Claire Madden-Smith, Senior Vice President, Juniper Pharma Services||September 8, 2016
    Combining expertise to get drug candidates through development

  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent